MX2015010077A - Terapia de combinacion para el tratamiento de neumonia nosocomial. - Google Patents

Terapia de combinacion para el tratamiento de neumonia nosocomial.

Info

Publication number
MX2015010077A
MX2015010077A MX2015010077A MX2015010077A MX2015010077A MX 2015010077 A MX2015010077 A MX 2015010077A MX 2015010077 A MX2015010077 A MX 2015010077A MX 2015010077 A MX2015010077 A MX 2015010077A MX 2015010077 A MX2015010077 A MX 2015010077A
Authority
MX
Mexico
Prior art keywords
treatment
combination therapy
nosocomial pneumonia
nosocomial
pneumonia
Prior art date
Application number
MX2015010077A
Other languages
English (en)
Inventor
Shampa Das
Jianguo Li
Johan Willem Mouton
Wright Nichols
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50114393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015010077(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2015010077A publication Critical patent/MX2015010077A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a un método de tratamiento de neumonía nosocomial usando una combinación de ceftazidima (una cefalosporina de tercera generación) y avibactam (un nuevo inhibidor de ß-lactamasa), opcionalmente con uno o más agentes terapéuticos adicionales.
MX2015010077A 2013-02-06 2014-02-06 Terapia de combinacion para el tratamiento de neumonia nosocomial. MX2015010077A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361761369P 2013-02-06 2013-02-06
PCT/GB2014/050354 WO2014122468A1 (en) 2013-02-06 2014-02-06 Combination therapy for the treatment of nosocomial pneumonia

Publications (1)

Publication Number Publication Date
MX2015010077A true MX2015010077A (es) 2016-01-25

Family

ID=50114393

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010077A MX2015010077A (es) 2013-02-06 2014-02-06 Terapia de combinacion para el tratamiento de neumonia nosocomial.

Country Status (13)

Country Link
US (1) US20150374673A1 (es)
EP (1) EP2953626A1 (es)
JP (1) JP6383367B2 (es)
KR (1) KR20150115761A (es)
CN (2) CN110302203A (es)
AU (1) AU2014213795B2 (es)
BR (1) BR112015018360B1 (es)
CA (1) CA2897446A1 (es)
CL (1) CL2015002180A1 (es)
MX (1) MX2015010077A (es)
RU (1) RU2684112C2 (es)
UA (1) UA115683C2 (es)
WO (1) WO2014122468A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3221313T3 (en) * 2014-11-17 2019-04-08 Entasis Therapeutics Ltd COMBINATION THERAPY FOR TREATING INFECTIONS WITH RESISTANT BACTERIA
CN107438610A (zh) 2015-03-31 2017-12-05 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
CN107531709B (zh) 2015-09-16 2020-10-23 吉林四环制药有限公司 β-内酰胺酶抑制剂及其用途
BR112018074985A2 (pt) * 2016-06-17 2019-03-12 Wockhardt Limited composições antibacterianas
LT3512851T (lt) 2016-09-16 2022-10-25 Entasis Therapeutics Limited Beta-laktamazės inhibitorių junginiai
US10434089B2 (en) 2017-01-25 2019-10-08 The Johns Hopkins University Avibactam and carbapenems antibacterial agents
US11046694B2 (en) 2017-05-08 2021-06-29 Entasis Therapeutics, Inc. Compounds and methods for treating bacterial infections
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
RU2746833C1 (ru) * 2020-08-03 2021-04-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Способ моделирования экспериментального воспаления легких у крыс
CN113413367A (zh) * 2021-08-16 2021-09-21 浙江尖峰药业有限公司 一种注射用阿维巴坦头孢甲肟复方粉针及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1861110B1 (en) * 2004-12-17 2014-03-26 Venus Remedies Limited Antibiotic combinations for providing total solution to the treatment of infections
CN101074235B (zh) * 2006-05-15 2010-05-12 中国药品生物制品检定所 头孢硫脒醇水化合物及其制备方法
CN101245080A (zh) * 2007-02-14 2008-08-20 山东轩竹医药科技有限公司 含有吡唑并三唑的头孢菌素衍生物
EP2410985A2 (en) * 2009-03-26 2012-02-01 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis

Also Published As

Publication number Publication date
CL2015002180A1 (es) 2015-11-27
JP2016507547A (ja) 2016-03-10
BR112015018360B1 (pt) 2022-03-22
CA2897446A1 (en) 2014-08-14
WO2014122468A1 (en) 2014-08-14
JP6383367B2 (ja) 2018-08-29
CN104994860A (zh) 2015-10-21
CN110302203A (zh) 2019-10-08
BR112015018360A2 (pt) 2017-07-18
AU2014213795B2 (en) 2016-10-13
US20150374673A1 (en) 2015-12-31
UA115683C2 (uk) 2017-12-11
KR20150115761A (ko) 2015-10-14
AU2014213795A1 (en) 2015-07-30
RU2015132369A (ru) 2017-03-13
EP2953626A1 (en) 2015-12-16
RU2684112C2 (ru) 2019-04-04

Similar Documents

Publication Publication Date Title
PH12020551397A1 (en) Cot modulators and methods of use thereof
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
MX2015010077A (es) Terapia de combinacion para el tratamiento de neumonia nosocomial.
MX2019013123A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
EA201691036A1 (ru) Новое соединение для лечения тяжелой гипогликемии
NZ711523A (en) Use of sedoheptulose for prevention or treatment of inflammation
CY1119212T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
UA91089U (uk) Застосування препарату "біоглобін-у" як препарату для корекції гіпотиреоїдних станів в експерименті
PH12015502304A1 (en) Use of pidotimod to treat irritable bowel syndrome
UA84663U (ru) Состав для лечения и профилактики острого альвеолита челюстей
EA201691907A1 (ru) Комбинированная терапия кураксинами
UA76756U (ru) Способ лечения псориаза